Formulation, stability and immunogenicity of a trivalent pneumococcal protein vaccine formulated with aluminum salt adjuvants
- 1 April 2012
- journal article
- Published by Elsevier BV in Vaccine
- Vol. 30 (19), 2981-2988
- https://doi.org/10.1016/j.vaccine.2012.02.038
Abstract
We investigated the immunogenicity, stability and adsorption properties of an experimental pneumococcal vaccine composed of three protein vaccine antigens; Pneumococcal histidine triad protein D, (PhtD), Pneumococcal choline-binding protein A (PcpA) and genetically detoxified pneumolysin D1 (PlyD1) formulated with aluminum salt adjuvants. Immunogenicity studies conducted in BALB/c mice showed that antibody responses to each antigen adjuvanted with aluminum hydroxide (AH) were significantly higher than when adjuvanted with aluminum phosphate (AP) or formulated without adjuvant. Lower microenvironment pH and decreased strength of antigen adsorption significantly improved the stability of antigens. The stability of PcpA and PlyD1 assessed by RP-HPLC correlated well with the immunogenicity of these antigens in mice and showed that pretreatment of the aluminum hydroxide adjuvant with phosphate ions improved their stability. Adjuvant dose-ranging studies showed that 28 μg Al/dose to be the concentration of adjuvant resulting in optimal immunogenicity of the trivalent vaccine formulation. Taken together, the results of theses studies suggest that the type of aluminum salt, strength of adsorption and microenvironment pH have a significant impact on the immunogenicity and chemical stability of an experimental vaccine composed of the three pneumococcal protein antigens, PhtD, PcpA, and PlyD1.Keywords
This publication has 38 references indexed in Scilit:
- Streptococcus pneumoniae Clonal Complex 199: Genetic Diversity and Tissue-Specific VirulencePLOS ONE, 2011
- Rapid Pneumococcal Evolution in Response to Clinical InterventionsScience, 2011
- Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed) [Prevenar 13®]Drugs, 2010
- Population Snapshot of EmergentStreptococcus pneumoniaeSerotype 19A in the United States, 2005The Journal of Infectious Diseases, 2008
- Serotype-Specific Problems Associated with Pneumococcal Conjugate VaccinationFuture Microbiology, 2008
- Pneumococcal Vaccination and Revaccination of Older AdultsClinical Microbiology Reviews, 2003
- Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines.Microbiological Reviews, 1995
- The Protective Efficacy of Polyvalent Pneumococcal Polysaccharide VaccineNew England Journal of Medicine, 1991
- Considerations for Formulating the Second-Generation Pneumococcal Capsular Polysaccharide Vaccine with Emphasis on the Cross-Reactive Types Within GroupsThe Journal of Infectious Diseases, 1983
- Antibody Response to Pneumococcal Vaccination in Children Younger than Five Years of AgeThe Journal of Infectious Diseases, 1983